HCV Research and News

Contact Us

Question or comments? Please feel free to contact us!

Email us at hcvresearchandnews@gmail.com

Home

Subscribe to: Posts (Atom)

Home
About
Contact Us
Hepatitis C Links
Hepatitis C Support
Clinical Trials (Right click to open in new window)

Translate

Follow Us!

[Get this widget]

Followers

Blog Archive

▼ 2017 (3)
- ▼ December (3)
  - ▼ Dec 08 (3)

► 2015 (57)
- ► April (48)
  - ► Apr 25 (5)
  - ► Apr 24 (4)
  - ► Apr 23 (12)
  - ► Apr 22 (3)
  - ► Apr 17 (1)
  - ► Apr 16 (4)
  - ► Apr 15 (2)
  - ► Apr 14 (2)
  - ► Apr 13 (1)
  - ► Apr 11 (7)
  - ► Apr 10 (3)
  - ► Apr 09 (4)
- ► March (9)
  - ► Mar 26 (1)
  - ► Mar 25 (1)
  - ► Mar 21 (1)
  - ► Mar 20 (5)
  - ► Mar 19 (1)

► 2014 (550)
- ► November (51)
  - ► Nov 11 (9)
  - ► Nov 10 (15)
  - ► Nov 09 (9)
  - ► Nov 08 (7)
  - ► Nov 07 (4)
  - ► Nov 06 (3)
  - ► Nov 05 (4)
- ► June (33)
  - ► Jun 23 (1)
  - ► Jun 22 (1)
  - ► Jun 20 (4)
  - ► Jun 19 (8)
  - ► Jun 17 (2)
  - ► Jun 16 (5)
  - ► Jun 15 (8)
  - ► Jun 14 (4)
- ► May (30)
  - ► May 16 (4)
  - ► May 15 (2)
  - ► May 14 (5)
  - ► May 08 (3)
  - ► May 06 (2)
  - ► May 05 (2)
  - ► May 04 (12)
- ► April (64)
  - ► Apr 22 (1)
  - ► Apr 12 (13)
  - ► Apr 11 (11)
  - ► Apr 10 (14)
  - ► Apr 09 (7)
  - ► Apr 08 (2)
  - ► Apr 07 (3)
  - ► Apr 04 (1)
  - ► Apr 03 (4)
  - ► Apr 02 (4)
  - ► Apr 01 (4)
- ► March (114)
  - ► Mar 31 (3)
  - ► Mar 28 (1)
  - ► Mar 27 (2)
  - ► Mar 26 (7)
  - ► Mar 24 (6)
  - ► Mar 22 (2)
  - ► Mar 21 (6)
  - ► Mar 20 (4)
  - ► Mar 19 (8)
  - ► Mar 18 (3)
  - ► Mar 17 (7)
  - ► Mar 16 (4)
  - ► Mar 15 (6)
  - ► Mar 14 (5)
  - ► Mar 13 (5)
  - ► Mar 12 (2)
  - ► Mar 11 (4)
  - ► Mar 10 (5)
  - ► Mar 08 (1)
  - ► Mar 07 (2)
  - ► Mar 06 (5)
  - ► Mar 05 (4)
  - ► Mar 04 (11)
  - ► Mar 03 (10)
  - ► Mar 01 (1)
- ► February (133)
  - ► Feb 27 (2)
  - ► Feb 26 (7)
  - ► Feb 25 (5)
  - ► Feb 24 (7)
  - ► Feb 23 (1)
  - ► Feb 22 (8)
  - ► Feb 21 (3)
  - ► Feb 20 (5)
  - ► Feb 19 (3)
  - ► Feb 18 (4)
  - ► Feb 17 (5)
  - ► Feb 15 (5)
  - ► Feb 14 (4)
  - ► Feb 13 (5)
  - ► Feb 12 (6)
  - ► Feb 11 (6)
  - ► Feb 10 (7)
  - ► Feb 09 (4)
  - ► Feb 08 (1)
  - ► Feb 07 (9)
  - ► Feb 06 (8)
  - ► Feb 05 (2)
  - ► Feb 04 (9)
  - ► Feb 03 (5)
  - ► Feb 02 (10)
  - ► Feb 01 (2)
- ► January (125)
  - ► Jan 31 (3)
  - ► Jan 30 (13)
  - ► Jan 29 (2)
  - ► Jan 24 (1)
  - ► Jan 23 (1)
  - ► Jan 22 (4)
  - ► Jan 21 (4)
  - ► Jan 20 (4)
  - ► Jan 19 (3)
  - ► Jan 17 (2)
  - ► Jan 16 (13)
  - ► Jan 15 (3)
  - ► Jan 14 (6)
  - ► Jan 13 (3)
  - ► Jan 12 (3)
  - ► Jan 11 (3)
  - ► Jan 10 (1)
  - ► Jan 09 (9)
  - ► Jan 08 (12)
  - ► Jan 07 (7)
  - ► Jan 06 (9)
  - ► Jan 05 (3)
  - ► Jan 03 (2)
  - ► Jan 02 (8)
  - ► Jan 01 (6)

► 2013 (1928)
- ► December (257)
  - ► Dec 31 (1)
  - ► Dec 30 (6)
  - ► Dec 29 (10)
  - ► Dec 27 (10)
  - ► Dec 23 (5)
  - ► Dec 22 (15)
  - ► Dec 20 (6)
  - ► Dec 19 (7)
  - ► Dec 18 (15)
  - ► Dec 17 (7)
  - ► Dec 16 (12)
  - ► Dec 15 (3)
  - ► Dec 14 (8)
  - ► Dec 13 (14)
  - ► Dec 12 (11)
  - ► Dec 11 (18)
  - ► Dec 10 (12)
  - ► Dec 09 (9)
  - ► Dec 08 (7)
  - ► Dec 07 (7)
  - ► Dec 06 (16)
  - ► Dec 05 (17)
  - ► Dec 04 (9)
  - ► Dec 03 (9)
  - ► Dec 02 (11)
  - ► Dec 01 (12)
- ► November (351)
  - ► Nov 30 (9)
  - ► Nov 29 (5)
  - ► Nov 28 (8)
  - ► Nov 27 (7)
  - ► Nov 26 (13)
  - ► Nov 25 (14)
  - ► Nov 24 (4)
  - ► Nov 23 (3)
  - ► Nov 22 (15)
  - ► Nov 21 (13)
  - ► Nov 20 (13)
  - ► Nov 19 (24)
  - ► Nov 18 (16)
  - ► Nov 17 (9)
  - ► Nov 16 (5)
  - ► Nov 15 (14)
  - ► Nov 14 (11)
  - ► Nov 13 (10)
  - ► Nov 12 (21)
  - ► Nov 11 (17)
  - ► Nov 10 (12)
  - ► Nov 09 (6)
  - ► Nov 08 (10)
  - ► Nov 07 (10)
  - ► Nov 06 (18)
  - ► Nov 05 (8)
  - ► Nov 04 (20)
  - ► Nov 03 (6)
  - ► Nov 02 (20)
  - ► Nov 01 (10)
- ► October (260)
  - ► Oct 31 (8)
  - ► Oct 30 (6)
  - ► Oct 29 (9)
  - ► Oct 28 (12)
  - ► Oct 27 (7)
  - ► Oct 26 (3)
  - ► Oct 25 (11)
  - ► Oct 24 (15)
  - ► Oct 23 (15)
  - ► Oct 22 (13)
  - ► Oct 21 (17)
  - ► Oct 20 (5)
  - ► Oct 19 (6)
  - ► Oct 18 (4)
  - ► Oct 17 (5)
  - ► Oct 16 (10)
  - ► Oct 15 (8)
  - ► Oct 14 (14)
  - ► Oct 13 (3)
  - ► Oct 12 (2)
  - ► Oct 11 (7)
  - ► Oct 10 (10)
  - ► Oct 09 (2)
  - ► Oct 08 (9)
  - ► Oct 07 (6)
  - ► Oct 06 (6)
  - ► Oct 05 (10)
  - ► Oct 04 (4)
  - ► Oct 03 (11)
  - ► Oct 02 (8)
  - ► Oct 01 (14)
- ► September (166)
  - ► Sep 30 (10)
  - ► Sep 29 (7)
  - ► Sep 27 (10)
  - ► Sep 26 (3)
  - ► Sep 25 (10)
  - ► Sep 24 (12)
  - ► Sep 23 (10)
  - ► Sep 22 (3)
  - ► Sep 21 (5)
  - ► Sep 18 (6)
  - ► Sep 17 (8)
  - ► Sep 16 (11)
  - ► Sep 15 (7)
  - ► Sep 14 (1)
  - ► Sep 13 (8)
  - ► Sep 12 (6)
  - ► Sep 10 (12)
  - ► Sep 09 (11)
  - ► Sep 07 (5)
  - ► Sep 06 (11)
  - ► Sep 05 (1)
  - ► Sep 04 (4)
  - ► Sep 02 (4)
  - ► Sep 01 (1)
- ► August (124)
  - ► Aug 31 (3)
  - ► Aug 30 (5)
  - ► Aug 29 (3)
  - ► Aug 28 (8)
  - ► Aug 27 (7)
  - ► Aug 25 (2)
  - ► Aug 24 (2)
  - ► Aug 23 (3)
  - ► Aug 22 (4)
  - ► Aug 21 (9)
  - ► Aug 20 (9)
  - ► Aug 19 (1)
  - ► Aug 18 (4)
  - ► Aug 17 (9)
  - ► Aug 16 (7)
  - ► Aug 15 (17)
  - ► Aug 14 (1)
  - ► Aug 13 (3)
  - ► Aug 12 (6)
  - ► Aug 11 (12)
  - ► Aug 03 (9)
- ► July (175)
  - ► Jul 31 (8)
  - ► Jul 30 (7)
  - ► Jul 29 (13)
  - ► Jul 28 (2)
  - ► Jul 27 (4)
  - ► Jul 26 (14)
  - ► Jul 25 (23)
  - ► Jul 24 (14)
  - ► Jul 23 (20)
  - ► Jul 11 (9)
  - ► Jul 10 (8)
  - ► Jul 09 (9)
  - ► Jul 08 (4)
  - ► Jul 07 (3)
  - ► Jul 05 (7)
  - ► Jul 04 (7)
  - ► Jul 03 (16)
  - ► Jul 02 (7)
- ► June (192)
  - ► Jun 27 (4)
  - ► Jun 26 (6)
  - ► Jun 25 (8)
  - ► Jun 24 (16)
  - ► Jun 23 (2)
  - ► Jun 22 (6)
  - ► Jun 21 (1)
  - ► Jun 20 (10)
  - ► Jun 19 (6)
  - ► Jun 18 (10)
  - ► Jun 17 (12)
  - ► Jun 16 (2)
  - ► Jun 15 (4)
  - ► Jun 14 (2)
  - ► Jun 13 (12)
  - ► Jun 12 (17)
  - ► Jun 11 (10)
  - ► Jun 10 (13)
  - ► Jun 09 (3)
  - ► Jun 08 (3)
  - ► Jun 07 (3)
  - ► Jun 06 (11)
  - ► Jun 05 (9)
  - ► Jun 04 (8)
  - ► Jun 03 (5)
  - ► Jun 02 (2)
  - ► Jun 01 (7)
- ► May (175)
  - ► May 31 (2)
  - ► May 30 (14)
  - ► May 28 (2)
  - ► May 27 (2)
  - ► May 26 (6)
  - ► May 24 (8)
  - ► May 23 (6)
  - ► May 22 (10)
  - ► May 21 (10)
  - ► May 20 (5)
  - ► May 19 (7)
  - ► May 18 (5)
  - ► May 17 (7)
  - ► May 15 (14)
  - ► May 14 (4)
  - ► May 13 (11)
  - ► May 12 (7)
  - ► May 10 (4)
  - ► May 09 (5)
  - ► May 08 (8)
  - ► May 07 (10)
  - ► May 06 (4)
  - ► May 05 (3)
  - ► May 04 (4)
  - ► May 03 (1)
  - ► May 02 (8)
  - ► May 01 (8)
- ► April (167)
  - ► Apr 30 (10)
  - ► Apr 29 (11)
  - ► Apr 28 (10)
  - ► Apr 27 (14)
  - ► Apr 26 (2)
  - ► Apr 25 (14)
  - ► Apr 24 (11)
  - ► Apr 23 (14)
  - ► Apr 22 (12)
  - ► Apr 21 (5)
  - ► Apr 20 (6)
  - ► Apr 19 (2)
  - ► Apr 18 (11)
  - ► Apr 17 (7)
  - ► Apr 16 (10)
  - ► Apr 15 (7)
  - ► Apr 14 (3)
  - ► Apr 13 (18)
- ► January (61)
  - ► Jan 12 (3)
  - ► Jan 11 (10)
  - ► Jan 10 (9)
  - ► Jan 09 (7)
  - ► Jan 08 (6)
  - ► Jan 07 (16)
  - ► Jan 06 (10)

► 2012 (1103)
- ► October (116)
  - ► Oct 16 (9)
  - ► Oct 15 (11)
  - ► Oct 12 (3)
  - ► Oct 11 (14)
  - ► Oct 10 (21)
  - ► Oct 06 (9)
  - ► Oct 05 (11)
  - ► Oct 04 (6)
  - ► Oct 03 (9)
  - ► Oct 02 (15)
  - ► Oct 01 (8)
- ► September (103)
  - ► Sep 29 (10)
  - ► Sep 28 (11)
  - ► Sep 22 (1)
  - ► Sep 21 (9)
  - ► Sep 20 (6)
  - ► Sep 17 (8)
  - ► Sep 14 (12)
  - ► Sep 13 (3)
  - ► Sep 12 (14)
  - ► Sep 11 (9)
  - ► Sep 10 (20)
- ► June (39)
  - ► Jun 28 (12)
  - ► Jun 13 (11)
  - ► Jun 12 (16)
- ► May (102)
  - ► May 24 (7)
  - ► May 23 (9)
  - ► May 21 (8)
  - ► May 20 (10)
  - ► May 16 (1)
  - ► May 13 (2)
  - ► May 11 (6)
  - ► May 10 (1)
  - ► May 09 (7)
  - ► May 08 (16)
  - ► May 07 (10)
  - ► May 04 (3)
  - ► May 03 (3)
  - ► May 02 (17)
  - ► May 01 (2)
- ► April (237)
  - ► Apr 30 (11)
  - ► Apr 29 (4)
  - ► Apr 28 (1)
  - ► Apr 27 (6)
  - ► Apr 26 (7)
  - ► Apr 25 (3)
  - ► Apr 24 (10)
  - ► Apr 23 (8)
  - ► Apr 22 (3)
  - ► Apr 21 (4)
  - ► Apr 20 (14)
  - ► Apr 19 (34)
  - ► Apr 18 (13)
  - ► Apr 17 (8)
  - ► Apr 16 (9)
  - ► Apr 14 (8)
  - ► Apr 13 (6)
  - ► Apr 12 (3)
  - ► Apr 11 (11)
  - ► Apr 10 (13)
  - ► Apr 09 (3)
  - ► Apr 08 (8)
  - ► Apr 06 (7)
  - ► Apr 05 (5)
  - ► Apr 04 (14)
  - ► Apr 03 (12)
  - ► Apr 02 (7)
  - ► Apr 01 (5)
- ► March (179)
  - ► Mar 31 (6)
  - ► Mar 30 (5)
  - ► Mar 28 (14)
  - ► Mar 27 (13)
  - ► Mar 26 (1)
  - ► Mar 25 (3)
  - ► Mar 23 (9)
  - ► Mar 22 (7)
  - ► Mar 21 (5)
  - ► Mar 20 (2)
  - ► Mar 19 (5)
  - ► Mar 17 (6)
  - ► Mar 16 (10)
  - ► Mar 15 (4)
  - ► Mar 14 (9)
  - ► Mar 13 (6)
  - ► Mar 12 (1)
  - ► Mar 11 (3)
  - ► Mar 10 (2)
  - ► Mar 09 (3)
  - ► Mar 08 (11)
  - ► Mar 07 (9)
  - ► Mar 06 (20)
  - ► Mar 05 (4)
  - ► Mar 04 (5)
  - ► Mar 02 (6)
  - ► Mar 01 (10)
- ► February (161)
  - ► Feb 29 (6)
  - ► Feb 28 (14)
  - ► Feb 27 (1)
  - ► Feb 26 (5)
  - ► Feb 24 (5)
  - ► Feb 23 (12)
  - ► Feb 22 (9)
  - ► Feb 21 (6)
  - ► Feb 20 (10)
  - ► Feb 18 (2)
  - ► Feb 17 (2)
  - ► Feb 16 (9)
  - ► Feb 15 (7)
  - ► Feb 14 (3)
  - ► Feb 13 (4)
  - ► Feb 12 (10)
  - ► Feb 10 (3)
  - ► Feb 09 (7)
  - ► Feb 08 (4)
  - ► Feb 07 (11)
  - ► Feb 06 (5)
  - ► Feb 05 (1)
  - ► Feb 04 (4)
  - ► Feb 03 (6)
  - ► Feb 02 (8)
  - ► Feb 01 (7)
- ► January (166)
  - ► Jan 31 (10)
  - ► Jan 30 (7)
  - ► Jan 27 (9)
  - ► Jan 26 (6)
  - ► Jan 25 (5)
  - ► Jan 24 (7)
  - ► Jan 23 (7)
  - ► Jan 21 (1)
  - ► Jan 20 (6)
  - ► Jan 19 (6)
  - ► Jan 18 (14)
  - ► Jan 17 (8)
  - ► Jan 13 (10)
  - ► Jan 12 (2)
  - ► Jan 11 (7)
  - ► Jan 10 (8)
  - ► Jan 09 (9)
  - ► Jan 08 (7)
  - ► Jan 06 (3)
  - ► Jan 05 (5)
  - ► Jan 04 (9)
  - ► Jan 03 (13)
  - ► Jan 02 (7)

► 2011 (559)
- ► December (100)
  - ► Dec 30 (1)
  - ► Dec 29 (4)
  - ► Dec 28 (11)
  - ► Dec 27 (11)
  - ► Dec 22 (8)
  - ► Dec 16 (6)
  - ► Dec 15 (3)
  - ► Dec 14 (6)
  - ► Dec 12 (4)
  - ► Dec 11 (8)
  - ► Dec 09 (2)
  - ► Dec 08 (6)
  - ► Dec 07 (7)
  - ► Dec 06 (9)
  - ► Dec 05 (14)
- ► November (44)
  - ► Nov 24 (3)
  - ► Nov 23 (5)
  - ► Nov 22 (9)
  - ► Nov 20 (1)
  - ► Nov 18 (5)
  - ► Nov 17 (12)
  - ► Nov 16 (1)
  - ► Nov 15 (8)
- ► July (26)
  - ► Jul 10 (3)
  - ► Jul 07 (7)
  - ► Jul 06 (2)
  - ► Jul 05 (5)
  - ► Jul 04 (1)
  - ► Jul 03 (8)
- ► June (93)
  - ► Jun 30 (5)
  - ► Jun 29 (6)
  - ► Jun 28 (4)
  - ► Jun 27 (7)
  - ► Jun 26 (13)
  - ► Jun 25 (3)
  - ► Jun 23 (9)
  - ► Jun 22 (8)
  - ► Jun 21 (9)
  - ► Jun 20 (17)
  - ► Jun 19 (12)
- ► May (5)
  - ► May 22 (3)
  - ► May 15 (1)
  - ► May 13 (1)
- ► April (57)
  - ► Apr 06 (10)
  - ► Apr 05 (10)
  - ► Apr 04 (23)
  - ► Apr 03 (14)
- ► March (70)
  - ► Mar 19 (12)
  - ► Mar 17 (5)
  - ► Mar 16 (4)
  - ► Mar 15 (3)
  - ► Mar 14 (6)
  - ► Mar 12 (3)
  - ► Mar 11 (6)
  - ► Mar 10 (6)
  - ► Mar 09 (7)
  - ► Mar 08 (18)
- ► February (21)
  - ► Feb 15 (1)
  - ► Feb 14 (5)
  - ► Feb 13 (9)
  - ► Feb 05 (1)
  - ► Feb 04 (5)
- ► January (143)
  - ► Jan 31 (8)
  - ► Jan 29 (2)
  - ► Jan 28 (3)
  - ► Jan 27 (3)
  - ► Jan 26 (6)
  - ► Jan 25 (8)
  - ► Jan 24 (9)
  - ► Jan 21 (2)
  - ► Jan 20 (8)
  - ► Jan 18 (7)
  - ► Jan 17 (7)
  - ► Jan 15 (3)
  - ► Jan 14 (4)
  - ► Jan 13 (2)
  - ► Jan 12 (8)
  - ► Jan 11 (7)
  - ► Jan 10 (2)
  - ► Jan 09 (7)
  - ► Jan 08 (4)
  - ► Jan 07 (7)
  - ► Jan 06 (6)
  - ► Jan 05 (8)
  - ► Jan 04 (7)
  - ► Jan 03 (4)
  - ► Jan 02 (3)
  - ► Jan 01 (8)

► 2010 (1273)
- ► December (119)
  - ► Dec 31 (9)
  - ► Dec 30 (1)
  - ► Dec 29 (2)
  - ► Dec 28 (8)
  - ► Dec 27 (1)
  - ► Dec 23 (1)
  - ► Dec 22 (7)
  - ► Dec 21 (3)
  - ► Dec 19 (15)
  - ► Dec 17 (4)
  - ► Dec 16 (1)
  - ► Dec 15 (8)
  - ► Dec 14 (7)
  - ► Dec 13 (13)
  - ► Dec 12 (2)
  - ► Dec 11 (6)
  - ► Dec 07 (2)
  - ► Dec 06 (6)
  - ► Dec 04 (10)
  - ► Dec 03 (6)
  - ► Dec 02 (2)
  - ► Dec 01 (5)
- ► November (200)
  - ► Nov 30 (9)
  - ► Nov 29 (6)
  - ► Nov 28 (2)
  - ► Nov 27 (3)
  - ► Nov 26 (5)
  - ► Nov 25 (3)
  - ► Nov 24 (6)
  - ► Nov 23 (6)
  - ► Nov 22 (7)
  - ► Nov 21 (4)
  - ► Nov 20 (12)
  - ► Nov 18 (7)
  - ► Nov 17 (9)
  - ► Nov 16 (5)
  - ► Nov 15 (5)
  - ► Nov 14 (12)
  - ► Nov 11 (4)
  - ► Nov 10 (10)
  - ► Nov 09 (3)
  - ► Nov 08 (6)
  - ► Nov 07 (10)
  - ► Nov 06 (10)
  - ► Nov 04 (7)
  - ► Nov 03 (12)
  - ► Nov 02 (16)
  - ► Nov 01 (21)
- ► October (155)
  - ► Oct 31 (13)
  - ► Oct 30 (16)
  - ► Oct 29 (7)
  - ► Oct 28 (9)
  - ► Oct 27 (7)
  - ► Oct 26 (5)
  - ► Oct 25 (10)
  - ► Oct 24 (13)
  - ► Oct 23 (19)
  - ► Oct 12 (2)
  - ► Oct 07 (7)
  - ► Oct 05 (11)
  - ► Oct 04 (2)
  - ► Oct 03 (4)
  - ► Oct 02 (9)
  - ► Oct 01 (21)
- ► September (97)
  - ► Sep 30 (5)
  - ► Sep 29 (3)
  - ► Sep 26 (2)
  - ► Sep 25 (10)
  - ► Sep 24 (3)
  - ► Sep 23 (3)
  - ► Sep 22 (13)
  - ► Sep 21 (8)
  - ► Sep 20 (15)
  - ► Sep 09 (9)
  - ► Sep 07 (8)
  - ► Sep 06 (1)
  - ► Sep 03 (8)
  - ► Sep 01 (9)
- ► August (332)
  - ► Aug 31 (13)
  - ► Aug 29 (7)
  - ► Aug 26 (11)
  - ► Aug 25 (8)
  - ► Aug 24 (17)
  - ► Aug 23 (15)
  - ► Aug 22 (9)
  - ► Aug 21 (9)
  - ► Aug 20 (12)
  - ► Aug 19 (18)
  - ► Aug 18 (17)
  - ► Aug 17 (19)
  - ► Aug 16 (7)
  - ► Aug 15 (10)
  - ► Aug 14 (5)
  - ► Aug 13 (11)
  - ► Aug 12 (14)
  - ► Aug 11 (7)
  - ► Aug 10 (17)
  - ► Aug 09 (10)
  - ► Aug 08 (9)
  - ► Aug 07 (8)
  - ► Aug 06 (9)
  - ► Aug 05 (8)
  - ► Aug 04 (16)
  - ► Aug 03 (21)
  - ► Aug 02 (13)
  - ► Aug 01 (12)
- ► July (257)
  - ► Jul 30 (6)
  - ► Jul 29 (6)
  - ► Jul 28 (10)
  - ► Jul 27 (17)
  - ► Jul 26 (11)
  - ► Jul 25 (8)
  - ► Jul 24 (10)
  - ► Jul 23 (10)
  - ► Jul 22 (12)
  - ► Jul 21 (12)
  - ► Jul 19 (8)
  - ► Jul 18 (2)
  - ► Jul 17 (7)
  - ► Jul 16 (9)
  - ► Jul 15 (14)
  - ► Jul 14 (12)
  - ► Jul 13 (11)
  - ► Jul 12 (8)
  - ► Jul 11 (12)
  - ► Jul 10 (1)
  - ► Jul 09 (10)
  - ► Jul 08 (5)
  - ► Jul 07 (11)
  - ► Jul 06 (11)
  - ► Jul 05 (12)
  - ► Jul 04 (2)
  - ► Jul 03 (6)
  - ► Jul 02 (5)
  - ► Jul 01 (9)
- ► June (113)
  - ► Jun 30 (13)
  - ► Jun 29 (5)
  - ► Jun 28 (12)
  - ► Jun 27 (5)
  - ► Jun 26 (4)
  - ► Jun 25 (4)
  - ► Jun 24 (5)
  - ► Jun 23 (7)
  - ► Jun 22 (5)
  - ► Jun 21 (3)
  - ► Jun 20 (4)
  - ► Jun 19 (13)
  - ► Jun 18 (12)
  - ► Jun 17 (4)
  - ► Jun 16 (1)
  - ► Jun 15 (7)
  - ► Jun 14 (9)

Labels

“Breakthrough Therapy” Designation "DC-TC" therapy "Warehousing patients" 2nd generation DAAs 3-nitrotyrosine AASLD 2010 AASLD 2011 AASLD 2012 AASLD 2013 AASLD clinical practice guidelines ABT-072 ABT-267 ABT-333 ABT-450 ABT-450/r ABT-450/r + ABT-333 + ANT-267 +/- Ribavirin ABT-450/r + ABT-333 + Ribavirin ABT-450/r-Ombitasvir + Dasabuvir +/- Ribavirin ABT-493 ABT450 + Ritonavir + ABT267 ABT450 + Ritonavir + ABT267 + ABT333 ABT450 + Ritonavir + ABT267 + ABT333 + Ribavirin ACA Access to Care Acetaminophen ACH-1625 ACH-2684 ACH-2928 ACH-3102 ACH-3102 + ACH-2684 ACH-3102 + sofosbuvir ACH-3102/Sovaprevir ACH-3422 Action Plan for the Prevention Care and Treatment of Viral Hepatitis (2014-2016) Acute HCV Acute Hepatitis Acute Liver Failure Acute-on-Chronic Liver Failure (ACLF). Addiction Advanced cirrhosis Advanced fibrosis Adverse Effects Alanine Aminotransferase (ALT) Albumin Alcohol Alcoholic Hepatitis Alcoholic Liver Disease Alcoholism Alisporivir (Deb025) Alisporivir+ribavirin Alpha-fetoprotein ALS-2158 ALS-2200 Ammonia levels ANA598 Anemia Anti-fibrotic Antidepressants Antioxidant Supplements Antiretroviral Therapy Antiviral Resistance APASL 2014 ARC-520 Artificial Livers Ascites ASH (alcoholic steatohepatitis) Asunaprevir Asunaprevir (BMS-650032) Atherosclerosis BARACLUDE® Barriers to care Bavituximab BI 207127 Bioartificial Liver Bioengineered liver Biopsy BIT225 BL-8020 BL-8030 Blood Basics Blood transfusion Blood-Brain Barrier BMS-650032 BMS-790052 BMS-791325 BMS-986094 (INX-189) Boceprevir Caffeine Cancer Cardiovascular disease Caregivers CF102 Chemopreventive Stratagies Chemostat Chemotherapy Child-Pugh Score Cholesterol Chronic Fatique Syndrome Chronic Kidney Disease (CKD) Chronic Liver Disease cirrhosis Cirrhosis Risk Score (CRS) Clinical Trials Coffee Cognition Cognitive impairment Colloidal Silver Compassionate use Complementary and alternative medications (CAM) Compliance Contraindications to anti-viral therapy Coronary artery disease (CAD) Corticisteroids Cost-effectiveness CROI 2014 Cryoglobulinemia Curcumin Current News Current Related Articles Current Research Cyclophilin inhibitors DAA-resistance mutations Daclatasvir Daclatasvir (BMS-790052) Daclatasvir (DCV)/Asunaprevir (ASV) Daclatasvir + Asunaprevir Daclatasvir + Peg-Ifn/Riba Daclatasvir + Sofosbuvir + Ribavirin Daclatasvir/Asunaprevir Daclatasvir/Asunaprevir/BMS-791325 Daclatasvir/asunaprevir+/-Peg-Ifn/Riba Daclatasvir+Asunaprevir+BMS-791325 Danoprevir Danoprevir + Peg-Ifn/Ribavirin Danoprevir/Ritonavir + Peg-Ifn/Ribavirin Danoprevir+Ritonavir (DNVr) Dasabuvir (also known as ABT-333) DCD (donation after cardiac death) DDW 2012 DDW 2013 Deceased-donor LT (DDLT) Decompensated Cirrhosis Deleobuvir (BI 207127) Dental health Depression Dermatology Diabetes Diet Dietary Supplements Difficult to treat patients Direct Acting Antivirals Discrimination Disease progression Donor-recipient Donor-Recipient Allocation Model (DReAM) Drug Induced Liver Failure Drug Interactions Drug Resistance Drug-drug interactions (DDIs) Drug-induced liver injury (DILI) Durability of SVR Dyslipidemia EASL 2011 EASL 2012 EASL 2013 EASL 2014 EASL Clinical Practice Guidelines EASL HCV Treatment Guidelines 2014 EASL-AASLD Special Conference Prague 2012 ECHO (Extension for Community Healthcare Outcomes) ELAD® Bioartificial Liver Elastography ELF test (Enhanced Liver Fibrosis test) eltrombopag Eltrombopag (Promacta) Emricasan Enhanced Liver Fibrosis Test Epidemiology eRVR Erythropoietin ESLD Esophageal Varices ESRD Estrogen EVR Exposures in Health Care Settings Extrahepatic manifestations Faldaprevir (BI 201335) Faldaprevir + deleobuvir + PPI-668 +/- Riba Faldaprevir + deleobuvir + Riba Faldaprevir + Peg-Ifn + Riba Faldaprevir + Peg-Inf/Ribavirin Faldaprevir/Deleobuvir+/-Riba Faldaprevir/Peg-Ifn/riba Faldaprevir+Deleobuvir+PPI-668 FASN Inhibitors Fatigue Fatty Liver Fatty Liver Disease FDA Draft Guidance on Hepatitis C Drug Development FDA Warnings Fibroscan FibroScan® Fibrosis FibroTest Fish Oil Fluvastatin Fructose Gender Gender-specific medicine Genetics Genotype Genotype 1 Genotype 1a Genotype 1b Genotype 2 Genotype 3 Genotype 4 Genotype 5 Genotype 6 Ginkgo biloba GR-MD-02 GR-MD-O2 GS 9190 GS 9256 GS-0938 GS-5816 GS-5885 GS-7977 GS-7977 (PSI-7977) GS-9451 GS-9669 GSK-2336805 GSK2336805 GSK2336805+Simeprevir Guest Blogger_Opiferum Guest_Blogger_Opiferum Guest_Blogger_StaceyCarmody Haemophilia Haemostasis Harm Reduction HAV HAV Vaccinations HBV HBV Advocacy HBV Awareness HBV Reactivation HBV Screening HBV Treatment HBV Vaccinations HBV/HCV Coinfection HCC HCC Diagnosis HCC Screening HCC Treatments HCV HCV Advocacy HCV Awareness HCV basics HCV Care HCV Complications HCV Diagnostics HCV Disease Burden and Cost HCV Education HCV Genotypes HCV genotyping HCV Guidelines HCV in Children HCV Prevalence HCV Prevention HCV Recurrence HCV Reinfection HCV Research HCV Risk Factors HCV Screening HCV Screening in Correctional Institutes HCV Support HCV Survival Outside the Body HCV Transmission HCV Treatment HCV Treatment Costs HCV Treatment in Prison HCV-related HCC HCV1 Health Care Health-related quality of life (HRQOL) Hemochromatosis Hemodialysis. Kidney Disease Hemoglobin Hemopurifier Hepatic Decompensation Hepatic Encephalopathy Hepatitis A Hepatitis B Reactivation Hepatitis Basics Hepatitis D Hepatitis E HepDirect™ Herbal Supplements HIV Awareness HIV Diagnostics HIV Education HIV medications HIV Prevention HIV Screening HIV Vaccine Trials HIV/AIDS HIV/AIDS Awareness HIV/AIDS Research HIV/AIDS Transmission HIV/HBV Coinfection HIV/HCV Coinfection IDU IDX184 IDX19368 IDX19370 IDX20963 IDX21437 IDX21459 IDX2963 IDX719 IL28B IL28B CC Immune disorders Immune System IMO-2125 Inactive chronic hepatitis B INCIVEK® (telaprevir) Incivo (telaprevir) Induction Therapy Injecting Drug Users (IDUs) Injecting practices Inosine Triphosphatase (ITPA) Inosine Triphosphatase (ITPA) Variants Insulin Resistance Interesting Articles Interferon Interferon Lambda Interferon- ineligible/intolerant (IN/I) Interferon-free Interferon/Riba-Free INX-189 IP-10 ITPA polymorphism (rs1127354) ITX5061 Kava Kidney Transplant Labs Late relapse Ledipasvir Ledipasvir+Vedroprevir+Tegobuvir+Ribavirin Ledispasvir LGD-7501 Lichen planus Lipid Metabolism Livatag(R) Live-Donor Liver Transplantation (LDLT) Liver Basics Liver Cancer Liver Damage Liver Disease Liver Disease Progression Liver Enzymes Liver Failure Liver fibrosis quantification Liver Function Liver function breath tests Liver Function Tests Liver Health Liver metabolism Liver Metastasis Liver Regeneration Liver Related Death Liver Related Mortality Liver Stiffness Liver Stiffness Measurement Liver toxicity Liver Transplant Liver Tumours Living Donor Living-donor liver transplantation (LDLT) Locteron Lucinda_Porter Lymphocytosis Lymphoma Lymphotropism Magnetic resonance elastography (MRE) Magnetic resonance laparoscopy (MRL) Maintenance Peginterferon Marijuana Markov model MBL-HCV1 Medical/Drug Scams Mediterranean Diet Medusa-formulated interferon-alpha ("IFN a-2b XL") MELD Men who have sex with men (MSM) Menopause Mental Health Mental Illness Mericitabine Mericitabine (RO5024048) Metabolic Factors Metabolic Risk Factors Metabolic syndrome Metabolite biomarkers Methadone Methadone Maintenance Treatment Program (MMTP microRNA microRNA-122 Milan Criteria Milk Thistle miR-122 Miravirsen Mixed genotype MK-5172 MK-5172 (100 mg) + MK-8742 (20 mg) + ribavirin MK-5172 (100 mg) + MK-8742 (50 mg) + ribavirin MK-5172/MK-8742 MK-5172/MK-8742 +/- RBV MK-8742 Morbidity Mortality Mother-to-Child Transmission Multidrug-resistant strains Muscle Cramps NAFLD NAFLD fibrosis score Naloxone NASH Nephrotoxicity Neupogen Neurological Complications Neuropathy Neuropsychological Complications Neutropenia New HCV Drugs Non-invasive Liver Diagnosis Noninvasive Biomarkers Noninvasive biopsy markers Nonresponders NS3/4A protease inhibitors NS4B NS5A Inhibitor NS5B NS5B polymerase inhibitors Null Responders Nutrition Nutritional Supplements Obesity Occupational Exposure Ocular complications Off-label use OLYSIO™ (simeprevir) Ombitasvir (also known as ABT-267) Opiate substitution therapy (OST) Opioid Dependence Opioid Maintenance Opioids Oral health OraQuick HCV Rapid Antibody Test Organ Allocation Organ Donation Organ Donation Awareness Organ Rejection Organ Transplant Ornithine Phenylacetate (OCR-002) Osteoporosis Other Health Issues Pain management Pan-Genotypic Pancreatic cancer Paracentesis Partial Responder Pediatrics Peg-Ifn/Ribavirin PEG-Interferon lambda (IL-29) Pegasys/Ribaviran Peginterferon Lambda‐1a Pegylated Interferon People who inject drugs (PWID) People who use drugs (PWUD) PEPFAR Personal Stories Personal Stories_Anonymous Personal Stories_Anonymous2 Personal Stories_Bernie Miller Personal Stories_Debbie Cole Personal Stories_Jenne Griffin-Accettura Personal Stories_Jerome Alex Personal Stories_Jerome Alex_Part 2 Personal Stories_Manaun Middleton Personal Stories_Mark Eckler Personal Stories_Opiferum Personal Stories_Rita Robinson Personal Stories_Terrie Lenhart-Jenson Personalized HCV Treatment Platelet count Polymerase Inhibitors Polymorphisms Portal Hypertension Posttransplant viral response (pTVR) Potassium PPI-338 PPI-461 PPI-668 Pre-exposure Prophylaxis (PrEP) Pre-transplant Pregnancy Prescription Assistance Pretransplant HCV Treatment Pretreatment anemia Prevalence and Natural History of HCV in Women Primary Biliary Cirrhosis Primary Care Physicians Probiotics Protease Inhibitor Proton pump inhibitors PSI-661 PSI-7977 PSI-938 Psychiatric Disorders Psychiatric Treatment Q80K polymorphism Quality of care Quality of Life Quantitative liver-function tests (QLFTs) Recurrence of HCV-related HCC. Recurrent HBV Recurrent HCV Regorafenib Reinfection Relapse Renal disease Renal Function Renal impairment Resistant–Associated Variants Response-guided Treatment Retinopathy Reversal of hepatic fibrosis RG7128 Ribavirin Ribavirin Dose Reduction Ribavirin-free Rifaximin Ritonavir Ritonavir boosted Danoprevir + Mericitabine Rituximab Romiplostim RVR Samatasvir Samatasvir (IDX719) SAMe Sexual Dysfunction Sexual Hormones Sexual Transmission Side-Effect Management Silibinin Silymarin Simeprevir Simeprevir (TMC435) Simeprevir + Peg-Ifn/Ribavirin Simeprevir + Samatasvir (IDX719 Simeprevir + samatasvir + TMC647055 + ritonavir +/- ribavirin Simeprevir + Sofosbuvir +/- Riba Simeprevir+Sofosbuvir Sjogren's Syndrome Sleep disturbances Sofosbuvir Sofosbuvir + Daclatasvir +/- Ribavirin Sofosbuvir + GS-5816 Sofosbuvir + GS-9669 +Ribavirin Sofosbuvir + Ledipasvir + Ribavirin Sofosbuvir + Peg-Ifn/Ribavirin Sofosbuvir + Ribavirin Sofosbuvir/ledipasvir Sofosbuvir/Ledipasvir + GS-0660 Sofosbuvir/Ledipasvir +/- Ribavirin Sofosbuvir/Ledipasvir Fixed Dose Combination with or w/o Ribavirin (Electron) Sofosbuvir/Ledipasvir Fixed Dose Combination with or w/o Ribavirin (Lonestar) Sofosbuvir/Ledipasvir/GS-9669 Sofosbuvir/Peg-Ifn/Riba Sofosbuvir/Riba Sofosbuvir/Simeprevir Sofosbuvir+ Daclatasvir Sofosbuvir+Ribavirin Sorafenib Sovaldi™ (Sofosbuvir) Sovaprevir sovaprevir + ACH-3102 + ribavirin Special populations Spirulina platensis Spleen stiffness Spontaneous HBV clearance Spontaneous HCV Clearance Squamous cell carcinoma antigens immunocomplex (SCCA-IC) SSDI STAT-C Statins Steatohepatitis Steatosis Stem Cells Stigma Substance Abuse Survival of HCV in syringes Survival of Hepatitis C Virus on Inanimate Surface SVR SVR(12) SVR(24) SVR(4) Tainted Blood Telaprevir Telaprevir-Resistant Variants TheraSphere® ThermoDox® Thrombocytopenia Thyroid abnormalities Thyroid Disease TIPS Tivantinib TMC-647055 TMC435 TMC647055 TMC649128 Traditional Chinese herbal therapies Traditional Chinese Medicine Transient elastography Transmission in a Clinical Setting Transplant Criteria Transplant Evaluation Transplant Lists Transplant-transmitted infection Treatment Adherence Treatment as Prevention (TasP) Treatment completion Treatment Deferral Treatment Duration Treatment Experienced Treatment Failure Treatment guidelines Treatment Naive Treatment outcomes Treatment Response Tremelimumab Truvada TT-034 Turmeric curcumin Ultrasound elastography (US elastography) Vaccines Vaniprevir (MK-7009) Vaniprevir + Peg-Ifn/Ribavirin Variceal Bleeding Vasculitis Vertical Transmission Veterans VICTRELIS™ (boceprevir) Vienna Declaration Viral Breakthrough Viral Clearance Viral Hepatitis Viral Hepatitis Action Plan Viral Hepatitis and Liver Cancer Control and Prevention Act Viral Load Viral Load Suppression Viral Relapse Viral Resistance Viremic Virologic Response Visceral Adiposity Index (VAI Vitamin A Vitamin B Vitamin B12 Vitamin D Vitamin E Viusid Von Willebrand Factor VX-135 VX-135 + Daclatasvir VX-222 Weekly_Top5 WHO Global policy report on the prevention and control of viral hepatitis WHO Hepatitis C Treatment Guidelines Wilson's Disease World AIDS Day World Hepatitis Day Zinc

FAIR USE NOTICE:

This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. It is being made available in an effort to advance the understanding of Hepatitis C, New hepatitis c drugs, Related clinical trials and ongoing research, HIV/HCV coinfection, HIV/AIDS, Other factors of liver disease, and so on. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.

The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute medical or health related advice.